Summary statistics (categorical variables)
| Characteristic | Number (%) |
| Age, years | |
| Median | 70 |
| Range | 59–81 |
| Sex | |
| Female | 22 (51) |
| Male | 21 (49) |
| COO subtype* | |
| Non-GCB | 9 (21) |
| GCB | 24 (56) |
| NK | 10 (23) |
| LDH (U/L) | |
| Median | 534 |
| IQR | 354–867 |
| Range | 178–4855 |
| Ann Arbor Staging | |
| I | 4 (9) |
| II | 5 (12) |
| III | 17 (40) |
| IV | 17 (40) |
| No of extranodal sites | |
| ≤1 | 32 (74) |
| >1 | 5 (14) |
| NK | 6 (12) |
| Performance status† | |
| ≤2 | 31 (72) |
| >2 | 11 (26) |
| NK | 1 (2) |
| IPI‡ | |
| 0 or 1 | 7 (16) |
| 2 | 11 (26) |
| 3 | 6 (14) |
| 4 | 12 (28) |
| 5 | 4 (9) |
| NK | 3 (7) |
| MYC expression (%) | |
| <40 | 16 (37) |
| ≥40 | 26 (60) |
| NK | 1 (2) |
| MYC translocation | |
| Absent | 16 (80)§ |
| Present | 4 (20)§ |
| MYC translocation present | |
| MYC expression >40% | 3 (75) |
| MYC expression <40% | 1 (25) |
| MYC translocation absent | |
| MYC expression >40% | 12 (75) |
| MYC expression <40% | 4 (25) |
| BCL2 expression (%) | |
| <50 | 6 (14) |
| ≥50 | 35 (82) |
| <70 | 9 (21) |
| ≥70 | 32 (74) |
| NK | 2 (5) |
| BCL2 translocation | |
| Absent | 15 (75) |
| Present | 5 (25) |
| BCL2 translocation present | |
| BCL2 expression >70% | 5 (100) |
| BCL2 expression <70% | 0 (0) |
| BCL2 translocation absent | |
| BCL2 expression >70% | 12 (80) |
| BCL2 expression <70% | 3 (20) |
| MYC expression >40 and BCL2 >50 (%) | |
| No | 19 (44) |
| Yes | 22 (51) |
| NK | 2 (5) |
| MYC expression >40 and BCL2 >70 (%) | |
| No | 22 (51) |
| Yes | 19 (44) |
| NK | 2 (5) |
| MYC expression >60 and BCL2 >50 (%) | |
| No | 22 (72) |
| Yes | 10 (23) |
| NK | 2 (5) |
| MYC expression >60 and BCL2 >70 (%) | |
| No | 33 (77) |
| Yes | 8 (19) |
| NK | 2 (5) |
| Ki67 (%) | |
| <90 | 30 (70) |
| >90 | 13 (30) |
| Double hit¶ | |
| No | 19 (44) |
| Yes | 2 (5) |
| NK | 22 (51) |
| Therapy | |
| No rituximab | 7 (16) |
| Rituximab containing | 36 (84) |
| Complete response** | |
| No | 18 (42) |
| Yes | 25 (58) |
| Relapsed-refractory after treatment | |
| No | 29 (67) |
| Yes | 12 (28) |
| NA | 2 (5) |
| Died | |
| No | 24 (56) |
| Yes | 19 (44) |
*Cell of origin (COO) based on the Hans algorithm.
†Performance status was calculated using Eastern Cooperative Oncology Group (ECOG) scoring and is based on the level of activity of the patient.
‡International Prognostic Index (IPI) is based on age, performance status, serum lactate dehydrogenase (LDH), extent of extranodal involvement and Ann Arbor staging. Where the IPI score could not be calculated, the minimum IPI score was calculated and used.
§Data are based on 20 patients with available cytogenetic data only.
¶Double hit denotes both translocation on MYC and BCL2 gene.
**Includes CT-based and Positron Emission Tomography - Computed Tomography (PET-CT)-based assessment of response.
GCB, germinal centre B-like; NA, not applicable; NK, not known.